Efficacy: number of participants who respond to treatment ‐ at 24 hours · adults (aged 18 years+) with depression in bipolar disorder
It is very uncertain whether ketamine changes efficacy: number of participants who respond to treatment ‐ at 24… compared with midazolam (very low certainty).
1 finding from 1 review
Remission · adults (aged 18 years+) with depression in bipolar disorder
It is very uncertain whether ketamine changes efficacy: number of participants who achieve remission ‐ at 24 hours compared with midazolam (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · adults (aged 18 years+) with depression in bipolar disorder
1 finding from 1 review
Efficacy: number of participants who respond to treatment ‐ at 24 hours · adults with Major Depressive Disorder
It is very uncertain whether ketamine changes efficacy: number of participants who respond to treatment ‐ at 24… compared with placebo (very low certainty).
1 finding from 1 review
OR 3.94 [1.54, 10.1]
Studies not reported
Very low
Withdrawals due to adverse events · adults with Major Depressive Disorder
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Efficacy: number of participants who respond to treatment ‐ at 24 hours · adults with Major Depressive Disorder
Esketamine may leads to higher efficacy: number of participants who respond to treatment ‐ at 24… compared with placebo (low certainty).
1 finding from 1 review
OR 2.11 [1.2, 3.68]
Studies not reported
Low
Remission · adults with Major Depressive Disorder
Esketamine probably leads to higher efficacy: number of participants who achieve remission ‐ at 24 hours… compared with placebo (moderate certainty).
1 finding from 1 review
OR 2.74 [1.71, 4.4]
Studies not reported
Moderate
Acceptability ‐ total dropouts · adults with Major Depressive Disorder
Esketamine showed no clear difference in acceptability: total dropouts№ of participants: 773(5 RCTs) compared with placebo (moderate certainty).
1 finding from 1 review
OR 1.58 [0.92, 2.73]
Studies not reported
Moderate
Withdrawals due to adverse events · adults with Major Depressive Disorder
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Remission · adults with Major Depressive Disorder
It is very uncertain whether ketamine changes efficacy: number of participants who achieve remission ‐ at 24 hours… compared with placebo (very low certainty).
1 finding from 1 review
OR 5.6 [1.07, 29.46]
Studies not reported
Very low
Acceptability ‐ total dropouts · adults with Major Depressive Disorder
It is very uncertain whether ketamine changes acceptability: total dropouts№ of participants: 201(6 RCTs) compared with placebo (very low certainty).
1 finding from 1 review
OR 1.25 [0.19, 8.28]
Studies not reported
Very low
Withdrawals due to adverse events · adults with Major Depressive Disorder
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Efficacy: number of participants who respond to treatment ‐ at 24 hours · adults with Major Depressive Disorder
It is very uncertain whether ketamine changes efficacy: number of participants who respond to treatment ‐ at 24… compared with midazolam (very low certainty).
1 finding from 1 review
OR 2.48 [1, 6.18]
Studies not reported
Very low
Remission · adults with Major Depressive Disorder
Ketamine showed no clear difference in efficacy: number of participants who achieve remission ‐ at 24 hours compared with midazolam (low certainty).
1 finding from 1 review
OR 2.21 [0.67, 7.32]
Studies not reported
Low
Acceptability ‐ total dropouts · adults with Major Depressive Disorder
Ketamine showed no clear difference in acceptability: total dropouts№ of participants: 72(1 RCT) compared with midazolam (low certainty).
1 finding from 1 review
OR 0.33 [0.05, 2.09]
Studies not reported
Low
Death or bronchopulmonary dysplasia at 36 weeks PMA · preterm infants with or at risk of respiratory distress syndrome
Surfactant administration via thin catheter (S‐TC) probably leads to lower death or bronchopulmonary dysplasia (BPD) at 36 weeks' postmenstrual… compared with surfactant administration through an endotracheal tube (S‐ETT) (moderate certainty).
1 finding from 1 review
Need for intubation within the first 72 hours · preterm infants with or at risk of respiratory distress syndrome
Surfactant administration via thin catheter (S‐TC) probably leads to lower need for intubation within the first 72 hours compared with surfactant administration through an endotracheal tube (S‐ETT) (moderate certainty).
1 finding from 1 review
Air leak requiring drainage · preterm infants with or at risk of respiratory distress syndrome
Surfactant administration via thin catheter (S‐TC) showed no clear difference in air leak requiring drainage compared with surfactant administration through an endotracheal tube (S‐ETT) (low certainty).
1 finding from 1 review
Severe intraventricular haemorrhage · preterm infants with or at risk of respiratory distress syndrome
Surfactant administration via thin catheter (S‐TC) may leads to lower severe intraventricular haemorrhage (grade III or IV) compared with surfactant administration through an endotracheal tube (S‐ETT) (low certainty).
1 finding from 1 review
Death during first hospitalisation (all causes) · preterm infants with or at risk of respiratory distress syndrome
Surfactant administration via thin catheter (S‐TC) may leads to lower death during first hospitalisation (all causes) compared with surfactant administration through an endotracheal tube (S‐ETT) (low certainty).
1 finding from 1 review